Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma

Détails

ID Serval
serval:BIB_5C50FB8D82E7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma
Périodique
Oncologist
Auteur(s)
Buchegger F., Press O. W., Delaloye Bischof A., Ketterer N.
ISSN
1083-7159
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
13
Numéro
6
Pages
657-667
Langue
anglais
Résumé
Advanced-stage follicular lymphoma is incurable by conventional treatment. Rituximab has been introduced in various combinations with chemotherapy and has resulted in a significantly superior treatment outcome compared with chemotherapy alone. Multiple studies have also shown the efficacy of radioimmunotherapy (RIT) both as a single agent and in combination with chemotherapy. Rituximab and RIT have clearly distinct mechanisms of action, the first acting exclusively as a biological treatment, while the second acts by a combination of biologic mechanisms and radiation effects. Despite the therapeutic efficacy of both approaches, the potential exists to further improve both modalities. Repeat administrations of RIT using appropriate radioisotopes for treatment of residual disease or new targeting strategies might afford additional benefits. Unlabeled antibody treatment could potentially benefit from the combination of antibodies directed against different target antigens or combination therapy with cytokines capable of further mobilizing patients' cellular defenses. In this review, we hypothesize that the combination of an optimized biological treatment together with radiolabeled antibodies and chemotherapy early in the disease course of advanced-stage follicular lymphoma may represent the best approach to achieve prolonged disease-free survival and eventually cure.
Mots-clé
Antibodies , Antibodies,Monoclonal , Antineoplastic Agents , drug therapy , Humans , Lymphoma,Follicular , methods , Patients , radiation effects , Radioimmunotherapy , radiotherapy , therapeutic use , therapy , Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/01/2009 23:13
Dernière modification de la notice
08/05/2019 19:08
Données d'usage